TWi successfully launches generic Labetalol HCl Tablets in TWi label

January 16, 2019. TWi Pharmaceuticals, Inc. (“TWi”) (Stock Ticker: 4180.TT) today announced that the official launch of Labetalol HCl Tablets (equivalent to Trandate®), which is an ANDA (“Abbreviated New Drug Application”) TWi codeveloped with a leading US-based CMO. This approval is the first in a six product codevelopment deal signed in 2018.

Labetalol HCl tablets are indicated for the treatment of hypertension. According to IQVIA data, the total sales of Labetalol HCl tablets in the US were approximately US $52 million for the 12 months ended November 2018.

About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier to entry generic prescription products ranging from oral controlled release dosage forms to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer unparalleled market opportunities in the United States. For more information on TWi Pharmaceuticals and its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., please visit www.twipharma.com

Contact :
Angela Luan
Finance/ Investor Relations
Email: angela.luan@twipharma.com